Citi opened an “upside 90-day catalyst watch” on shares of Stryker (SYK) while keeping a Buy rating on the name with a $420 price target The firm believes fundamentals in the U.S. medical technology sector remain “healthy” despite the recent volatility. Stryker has reported consistent double-digit revenue and earnings growth, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker announces launch of SmartHospital Platform
- Stryker price target raised to $400 from $386 at UBS
- Walmart downgraded, Etsy upgraded: Wall Street’s top analyst calls
- Stryker initiated with an Outperform at William Blair
- Stryker: Expanding Breast Reconstruction Leadership Warrants Premium Valuation and Buy Rating